Compass Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Compass Therapeutics Inc.
- Former names
- Olivia Ventures, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CMPX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001738021
Board of directors
- Since 2023
-
David M. Wurzer · DirectorSince 2023
-
Ellen Chiniara · DirectorSince 2023
-
James P. Boylan · DirectorSince 2024
-
Mary Ann Gray · DirectorSince 2023
-
Philip Ferneau · DirectorSince 2023
-
Richard S. Lindahl · DirectorSince 2023
-
Thomas J. Schuetz · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Vered Bisker-Leib · Director · CHIEF EXECUTIVE OFFICERSince 2024
Chief executives
Thomas J. Schuetz
· CHIEF EXECUTIVE OFFICER
Dates unknown
Vered Bisker-Leib
· CHIEF EXECUTIVE OFFICER
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.5%
-
84.9%
Board connections
3 of this board's directors also sit on 11 other boards.
- via Carl L. Gordon and Mary Ann Gray
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via James P. Boylan
- via Carl L. Gordon
- via James P. Boylan
- via Carl L. Gordon
- via Mary Ann Gray
- via Carl L. Gordon
- via James P. Boylan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,850
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 24, 2026 | Lerner Neil Officer (Chief Accounting Officer) | Open-market purchase | +2,500 | $1.14 | $2,850 |
| Apr 29, 2026 | Anderman Jonathan Officer (General Counsel) | Grant or award | +25,000 | $1.89 | $47,250 |
| Apr 29, 2026 | Lerner Neil Officer (Chief Accounting Officer) | Grant or award | +15,000 | $1.89 | $28,350 |
| Feb 8, 2026 | Thomas J. Schuetz Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −36,687 | $6.52 | $239,199 |
| Jan 9, 2026 | Thomas J. Schuetz Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −46,777 | $5.35 | $250,257 |
| Jan 2, 2026 | Shin Barry Officer (CFO) | Grant or award | +125,000 | $5.17 | $646,250 |
| Jan 2, 2026 | Thomas J. Schuetz Director, Officer (CEO) | Grant or award | +250,000 | $5.17 | $1,292,500 |
| Jan 2, 2026 | Lerner Neil Officer (Chief Accounting Officer) | Grant or award | +62,500 | $5.17 | $323,125 |
| Jan 2, 2026 | Anderman Jonathan Officer (General Counsel) | Grant or award | +150,000 | $5.17 | $775,500 |
| Nov 16, 2025 | Thomas J. Schuetz Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −44,025 | $4.83 | $212,641 |
| May 27, 2025 | Thomas J. Schuetz Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +10,000 | $2.11 | $21,100 |
| Apr 9, 2025 | Carl L. Gordon Director, 10% owner | Open-market sale | −3,571,428 | $1.59 | $5,678,571 |
| Apr 9, 2025 | OrbiMed Capital GP VI LLC Director, 10% owner | Open-market sale | −3,571,428 | $1.59 | $5,678,571 |
| Apr 7, 2025 | Anderman Jonathan Officer (Gen Counsel & Corporate Sec) | Open-market purchase | +20,000 | $1.54 | $30,800 |
| Apr 7, 2025 | Lerner Neil Officer (CHIEF ACCOUNTING OFFICER) | Open-market purchase | +20,000 | $1.42 | $28,400 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.